News & Views

FGF-23 as a Biomarker for Identification of CKD Patients at Risk of Rapid Progression to ESRD (Part 2)

The development of novel biomarkers for CKD remains a top priority for improving diagnosis and management of CKD. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)’s CKD Biomarkers Consortium list 15 ongoing studies of novel CKD biomarkers. Until these new biomarkers are fully proven however, nephrologists should…

Read more

Date of publication:
April 16, 2015

News & Views

FGF-23 as a Biomarker for Identification of CKD Patients at Risk of Rapid Progression to ESRD (Part 1)

New strategies that could help prevent both the initial development of CKD and progression of established disease are of high interest to the medical community, given the high prevalence of CKD, and its strong associations with cardiovascular disease (CVD), end-stage renal disease (ESRD) and mortality.[1] Validated, effective biomarkers of CKD…

Read more

Date of publication:
April 9, 2015

News & Views

Phosphate & FGF-23 (Part 2) – distinct therapies for distinct causes of cardiovascular events?

A recent review article by Sciallia & Wolf outlines how serum FGF-23 and serum phosphate may influence cardiac physiology by distinct mechanisms.[1] As a result, effective treatment strategies may need to “simultaneously control both factors, instead of targeting one at expense of the other.” What are the available therapeutic options…

Read more

Date of publication:
October 17, 2014

News & Views

ERA-EDTA (Part 7) – Should FGF-23 levels be used to guide treatment with phosphate binders in pre-dialysis CKD?

Nephrologist opinion on when to initiate phosphate binder treatment in pre-dialysis CKD remains divided, at least on the evidence of several discussions at this year’s ERA-EDTA Congress. In the Bone and Mineral Disorders symposium at the 2014 ERA-EDTA Congress, Prof. Markus Ketteler suggested that the optimal time point to start…

Read more

Date of publication:
September 25, 2014

News & Views

Possible therapeutic strategies to lower FGF-23

Twelve years after the discovery of the hormone FGF-23 (fibroblast growth factor 23), many therapeutic options for targeting FGF-23 levels are emerging. Myles Wolf’s latest review paper [1] addresses the pertinent question as to whether CKD treatment regimens should now be tailored to address FGF-23 levels in addition to those…

Read more

Date of publication:
September 7, 2012

News & Views

Will FGF-23 become a critical marker in CKD management?

Welcome to our third instalment in our FGF-23 series exploring this potential marker and therapeutic target for chronic kidney disease. The position of FGF-23 as a biomarker of bone metabolism is progressing steadily. Last year, Isakova’s seminal study [1] reported that circulating FGF-23 concentrations were an independent predictor of progression…

Read more

Date of publication:
August 24, 2012

News & Views

Can FGF-23 predict clinical outcomes in CKD?

Numerous reports have linked elevated FGF-23 levels to the main adverse clinical outcomes in CKD: progression to end-stage renal disease (ESRD), cardiovascular disease, and death. Cross-sectional studies have also shown that increased FGF-23 levels in patients with CKD are associated with adverse systemic effects, increased mortality and deterioration of renal…

Read more
Professor Adrian Covic
Expert article by:
Professor Adrian Covic

Date of publication:
August 13, 2012

News & Views

The clinical significance of FGF-23 in CKD

A proliferation of studies linking excess levels of the endocrine hormone fibroblast growth factor 23 (FGF-23) to adverse renal and cardiovascular outcomes in patients with Chronic Kidney Disease (CKD) is setting the stage for new clinical trials, which could lead to FGF-23 becoming an important marker and/or therapeutic target in…

Read more
Professor Adrian Covic
Expert article by:
Professor Adrian Covic

Date of publication:
July 30, 2012

Login

You are about to leave Compact-Renal.com

Clicking the "Continue" link below will take you to an external website. Compact Renal is not responsible for the contents of any external website. Compact Renal is providing these links to you as a convenience, and the inclusion of any links does not imply endorsement of the linked site by Compact Renal.

Do you wish to continue?

Continue Cancel